With Cirrhosis

TABLE 120: SVR GENOTYPE 1 WITH CIRRHOSIS TREATMENT-EXPERIENCED WITH PRIORNULL RESPONSE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENTCOMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
T12 PR48 q8	PR48	0.85 (0.19 to 3.36)	-2.33 (-29.77 to 17.66)
SIM12 PR48		0.58 (0.10 to 2.47)	-6.56 (-33.68 to 13.51)
SOF12 + LDV12 + RBV12		4.36 (1.28 to 16.72)	61.05 (6.95 to 87.70)
SIM12 + SOF12		3.36 (0.70 to 12.86)	42.84 (-6.07 to 80.39)
SOF12 + SIM12 + RBV12		2.96 (0.43 to 12.11)	35.22 (-13.28 to 79.62)
SOF12 + PR12		1.64 (0.12 to 7.97)	9.71 (-25.84 to 69.83)
SIM12 PR48	T12 PR48 q8	0.68 (0.22 to 1.64)	-4.11 (-16.87 to 8.17)
SOF12 + LDV12 + RBV12		5.10 (2.12 to 16.17)	64.16 (16.53 to 87.52)
SIM12 + SOF12		3.86 (1.03 to 13.05)	45.35 (0.46 to 82.59)
SOF12 + SIM12 + RBV12		3.43 (0.69 to 11.76)	38.10 (-4.11 to 79.91)
SOF12 + PR12		1.83 (0.17 to 9.01)	11.88 (-16.29 to 72.93)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + LDV12 + RBV12	SIM12 PR48	7.59 (2.30 to 37.73)	68.96 (18.82 to 91.68)
SIM12 + SOF12		5.65 (1.60 to 24.60)	49.82 (5.26 to 85.54)
SOF12 + SIM12 + RBV12		4.89 (1.28 to 20.33)	42.35 (1.87 to 83.40)
SOF12 + PR12		2.68 (0.28 to 15.78)	16.25 (-10.12 to 76.31)
SIM12 + SOF12	SOF12 + LDV12 + RBV12	0.80 (0.16 to 2.11)	-15.90 (-72.30 to 39.85)
SOF12 + SIM12 + RBV12		0.71 (0.11 to 1.93)	-21.80 (-78.06 to 35.95)
SOF12 + PR12		0.37 (0.03 to 1.45)	-46.33 (-89.22 to 20.46)
SOF12 + SIM12 + RBV12	SIM12 + SOF12	0.90 (0.17 to 3.75)	-6.29 (-63.10 to 54.77)
SOF12 + PR12		0.49 (0.08 to 1.13)	-25.54 (-60.87 to 5.99)
SOF12 + PR12	SOF12 + SIM12 + RBV12	0.56 (0.05 to 3.57)	-19.56 (-77.39 to 44.90)
Random effect model	Residual deviance	29.34 vs. 31 data points	
	Deviance information criteria	145.523	
Fixed effect model	Residual deviance	29.3 vs. 31 data points	
	Deviance information criteria	145.001	

CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus. Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.